Shenzhen Hanyu Pharmaceutical (“Hybio”) is a leading bio-pharmaceutical company in China that focuses on the research, development, production and sales of therapeutic peptides and peptide-based drugs. Based on its strong R&D platform, the Company’s business has covered the entire peptide value chain from CRO (Contract Research Organization), CMO (Contract Manufacturer Organization) to finished formulations. Hybio has already brought eight peptide drugs to the Chinese market and has built up a robust pipeline, with three drugs in registration and many more under development. Hybio entered the CRO/CMO businesses in 2005 and has made significant progress due to its superior quality and cost advantage.
Location: China, Guangdong Province, Shenzhen
Employees: 501-1000
Founded date: 1998